Avidity Biosciences, Inc. (RNAM)
Feb 27, 2026 - RNAM was delisted (reason: acquired by NVS)
71.36
0.00 (0.00%)
Inactive · Last trade price
on Feb 26, 2026
Avidity Biosciences Employees
Avidity Biosciences had 511 employees as of December 31, 2025. The number of employees increased by 120 or 30.69% compared to the previous year.
Employees
511
Change (1Y)
120
Growth (1Y)
30.69%
Revenue / Employee
$36,703
Profits / Employee
-$1,339,787
Market Cap
n/a
Employees Chart
RNAM News
- 10 days ago - Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies - PRNewsWire
- 11 days ago - Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 14 days ago - Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - PRNewsWire
- 19 days ago - The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire
- 5 weeks ago - Avidity Biosciences Announces Expected Record Date for Spin-Off - PRNewsWire
- 5 weeks ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 5 weeks ago - Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Accesswire
- 7 weeks ago - Pharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters